Purpose of this Study
We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Have solid tumor(s) that are locally advanced or metastatic</li>
<li>Have a documented KRAS G12D mutation</li>
<li>Have worsened following standard therapy</li></ul>
For more information about who can join this study, contact the study team at 919-668-1861.
<li>Have solid tumor(s) that are locally advanced or metastatic</li>
<li>Have a documented KRAS G12D mutation</li>
<li>Have worsened following standard therapy</li></ul>
For more information about who can join this study, contact the study team at 919-668-1861.
What is Involved?
If you choose to join this study, you will:<ul>
<li>Take the study drug by mouth every day</li>
<li>Have your tumor biopsied</li>
<li>Give blood and urine samples</li>
<li>Have regular CT or MRI scans</li></ul>
<li>Take the study drug by mouth every day</li>
<li>Have your tumor biopsied</li>
<li>Give blood and urine samples</li>
<li>Have regular CT or MRI scans</li></ul>
Study Details
Full Title
[RMC-9805-001] Phase 1/1b, multicenter, open-label, study of RMC-9805 in participants with advanced KRASG12D-mutant solid tumors
Principal Investigator
John
Strickler
Protocol Number
PRO00114818
NCT ID
NCT06040541
Phase
I
Enrollment Status
Open to Enrollment